Trial Information
Generic NameGalantamineProduct NameRAZADYNE®Therapeutic AreaBehaviors and Mental DisordersEnrollment636% Female62%% White91%
Product ClassAlzheimer's Disease - Cholinesterase InhibitorsSponsor Protocol NumberGAL-USA-1Data PartnerJohnson & JohnsonCondition StudiedAlzheimer DiseaseMean/Median Age (Years)75.7
Supporting Documentation
- Collected Datasets Available
- Data Definition Specification Available
- Protocol with Amendments Available
- Statistical Analysis Plan Available
- Clinical Study Report Available
Approved Data Requests Associated with this Trial
- 2022-5053 : Adverse events reported in association with APOE genotype during clinical trials
- 2021-4836 : Adverse events of acetylcholinesterase inhibitors - systematic review and meta-analysis of double-blind randomized controlled trials
- 2016-0765 : Improving the statistical analysis of cognitive outcomes in randomised controlled trials: The ?Optimising the Analysis of Cognition? Collaboration
- 2015-0592 : Detection of uninformative clinics during the trial of a new drug using statistical and machine learning techniques